CDXS Stock Forecast: Codexis, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.04
−9.57% on the day

The median 12-month analyst price target for Codexis, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$117.3M
Ticker Nerd rank
40/ 100
Median analyst target
$5.00
Analysts covering
8
Revenue$14.9M−2.7% y/y
Operating income−$11.2M
Net income−$12.0M
Free cash flow−$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.3%
1M
−21.2%
YTD
−36.2%
1Y
−35.8%
From 52W high
−63.5%
From 52W low
+8.3%
$0.96
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Codexis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
40/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
69
Accruals
46
Value
46
Revisions
37
Volatility
21
Issuance
17
Momentum
16

Growth (99): Sales and profits are climbing, and climbing faster than before.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CDXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26CDXSHigh $11.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6
Buy
2
Hold
0
Sell
$2.00
Low
$5.00
Median
$11.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Nov 2026Stephens & Co.ReiteratesOverweight$5.00
17 Aug 2026Piper SandlerMaintainsOverweight$9.00 → $8.00
22 Nov 2024Cantor FitzgeraldReiteratesOverweight$11
15 Nov 2024Cantor FitzgeraldReiteratesOverweight$11
4 Nov 2024BenchmarkReiteratesHold—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight—
29 Aug 2024Cantor FitzgeraldReiteratesOverweight—
19 Aug 2024BenchmarkDowngradeHold—
9 Aug 2024Cantor FitzgeraldReiteratesOverweight—
30 May 2024Cantor FitzgeraldInitiatesOverweight—
3 May 2024BenchmarkReiteratesBuy—
29 Feb 2024BenchmarkUpgradeBuy—
7 Nov 2023BenchmarkDowngradeHold—
6 Nov 2023Piper SandlerMaintainsOverweight—
1 Sept 2023BenchmarkReiteratesBuy—
14 Aug 2023StifelMaintainsBuy—
21 July 2023Stephens & Co.ReiteratesOverweight—
9 May 2023BenchmarkMaintainsBuy—
9 May 2023HC Wainwright & Co.DowngradeNeutral—
17 Apr 2023Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CDXS.

Market Radar

This page is one stock. Monday covers all of them.

CDXS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CDXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Codexis, Inc. returned −35.8% against +9.2% for the S&P 500, dividends included.

CDXS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26CDXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CDXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.3×

Cheaper than 60% of US stocks

Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
76.5%

Higher than 88% of US stocks

Operating margin
−14.4%

Higher than 24% of US stocks

Net margin
—
Returns & dividend
Return on equity
−42.9%

Higher than 24% of US stocks

Return on assets
−5.9%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Codexis, Inc. has a market value of $117.3M and an enterprise value of $116.9M.

  • Revenue in the twelve months to 30 June 2026: $77.7M. The latest quarter shrank 2.7% year on year.

  • Net income over the same four quarters: −$30.7M, a −39.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 91.4M.

  • Codexis, Inc. employs 146 people — $532K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

CDXS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CDXSCodexis, Inc.$117.3M40
ENGNenGene Therapeutics, Inc.$124.0M21
NRXPNRX Pharmaceuticals, Inc.$124.1M19
MGNXMacroGenics, Inc.$125.2M87
FATEFate Therapeutics, Inc.$122.1M85
ALXOALX Oncology Holdings, Inc.$125.4M40
NTHINeOnc Technologies Holdings, Inc.$119.8M31

Take a look at CDXS’s peer groups, ranked by the model: materials stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Codexis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CDXS

What is the CDXS stock price forecast for 2026-2027?

The median 12-month analyst price target for Codexis, Inc. is $5, with estimates ranging from $2 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CDXS stock a buy right now?

Of the 8 analysts covering Codexis, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Codexis, Inc. 40 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDXS?

As at 18 Nov 2026, Codexis, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CDXS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $5, and Ticker Nerd's factor model ranks Codexis, Inc. 40 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CDXS stock forecast for 2030?

No analyst covering Codexis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $11 over the next 12 months.

How has CDXS stock performed over the past year?

Codexis, Inc. returned -35.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Codexis, Inc. do?

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications.

Company

About Codexis, Inc.

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.

CEO Dr. Alison Moore Ph.D. · 146 employees · United States · https://www.codexis.com